TY - JOUR
T1 - All-trans retionic ACid in the treatment of myelodysplastic syndromes
AU - Visani, G.
AU - Tosi, P.
AU - Manfroi, S.
AU - Ottaviani, E.
AU - Finelli, C.
AU - Cenacchi, A.
AU - Bendandi, M.
AU - Tura, S.
AU - Imamura, Mashiro
AU - Kasai, Masharu
AU - Zhu, Xiaofan
AU - Kobayashi, Sumiko
AU - Hashino, Satoshi
AU - Higa, Toshio
AU - Sakurada, Keisuke
AU - Asaka, Masahiro
PY - 1995
Y1 - 1995
N2 - Myelodysplastic syndromes (MDS) are a group of hematopoietic disorders characterized by uni- or multilineage maturation defects of the bone marrow. Controversial therapeutic results have been obtained using growth factors or differentiating agents such as 134s retinoic acid. In this pilot study we evaluatedthe effects of all-trans retinoic acid (ATRA) in 10 MDS patients (5 male, 5 female). Six patients had refractory anemia (RA), I had refractory anemia with excess of blasts (RAEB), and 3 had refractory anemia with excess of blasts in transformation (RAEB-t). All patients received the same dose of ATRA (45 mg/sqm/day) orally for 6 weeks. A rise in hemoglobin concentration >Ig/dl was observed in 3/10 patients, while 5/10 patients showed an increase in granulocyte count >0.5 × 109/1 without concomitant increase in the percentage of blast cells in the bone marrow. A rise in the platelet count >50 × 109/1 was observed in 1/10 patients. All the effects were transient and maximal responses were obtained by the fourth week of treatment. Thereafter, the peripheral blood counts started todrop again, reaching pre-therapy values by the end of the treatment. This phcnomenon could be attributed either to the exhaustion of an ATRA-responding cell pool, the development of cellular resistance to ATRA or to a reduction of plasma ATRA levels after prolonged treatrncnt. According to our results, it seems that ATRA might have therapeutic efficacy in MDS, particularly if its effect Interleukin-I receptor type I (IL-IR), IL-2 receptor a subunit (IL-2R) and IL-6 receptor a subunit
AB - Myelodysplastic syndromes (MDS) are a group of hematopoietic disorders characterized by uni- or multilineage maturation defects of the bone marrow. Controversial therapeutic results have been obtained using growth factors or differentiating agents such as 134s retinoic acid. In this pilot study we evaluatedthe effects of all-trans retinoic acid (ATRA) in 10 MDS patients (5 male, 5 female). Six patients had refractory anemia (RA), I had refractory anemia with excess of blasts (RAEB), and 3 had refractory anemia with excess of blasts in transformation (RAEB-t). All patients received the same dose of ATRA (45 mg/sqm/day) orally for 6 weeks. A rise in hemoglobin concentration >Ig/dl was observed in 3/10 patients, while 5/10 patients showed an increase in granulocyte count >0.5 × 109/1 without concomitant increase in the percentage of blast cells in the bone marrow. A rise in the platelet count >50 × 109/1 was observed in 1/10 patients. All the effects were transient and maximal responses were obtained by the fourth week of treatment. Thereafter, the peripheral blood counts started todrop again, reaching pre-therapy values by the end of the treatment. This phcnomenon could be attributed either to the exhaustion of an ATRA-responding cell pool, the development of cellular resistance to ATRA or to a reduction of plasma ATRA levels after prolonged treatrncnt. According to our results, it seems that ATRA might have therapeutic efficacy in MDS, particularly if its effect Interleukin-I receptor type I (IL-IR), IL-2 receptor a subunit (IL-2R) and IL-6 receptor a subunit
KW - All-trans retinoic acid
KW - Bone marrow transplantaion
KW - Cytokine
KW - Cytokine receptor
KW - Differetatopm
KW - Graft-versus-host disease
KW - Myelodysplasia
KW - Venooculusive diseae of the liver
UR - http://www.scopus.com/inward/record.url?scp=0029155541&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029155541&partnerID=8YFLogxK
U2 - 10.3109/10428199509107898
DO - 10.3109/10428199509107898
M3 - Article
C2 - 8535219
AN - SCOPUS:0029155541
VL - 19
SP - 277
EP - 280
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 3-4
ER -